Related Experiment Videos
No association between C-reactive protein gene polymorphisms and decrease of C-reactive protein serum concentration
Stéphanie Willot1, Severine Vermeire, Marc Ohresser
1François-Rabelais University, Immuno-Pharmaco-Genetics of Therapeutic Antibodies Research Group (UPRES EA 3853), Tours, France.
Pharmacogenetics and Genomics
|December 14, 2005
Summary
Genetic variations in the C-reactive protein (CRP) gene do not influence infliximab treatment response in Crohn's disease patients. This study found no linkage disequilibrium between CRP and FCGR3A genes, and CRP polymorphisms did not affect treatment outcomes.
Area of Science:
- Genetics
- Immunology
- Gastroenterology
Background:
- Previous research indicated an association between FCGR3A V/F polymorphism and infliximab response in Crohn's disease.
- The C-reactive protein (CRP) and FCGR3A genes are located on the same chromosomal locus (1q23).
Purpose of the Study:
- To investigate potential linkage disequilibrium (LD) between CRP and FCGR3A genes.
- To determine if CRP gene polymorphisms are associated with infliximab treatment response in Crohn's disease patients, specifically focusing on CRP level reduction.
Main Methods:
- Genotyping of FCGR3A (V/F) and three CRP polymorphisms (-717G/A, 1444C/T, CRP 4A/G) in 206 healthy donors and 189 Crohn's disease patients.
- Assessment of clinical and biological (CRP decrease) response to infliximab treatment.
- Statistical analysis to evaluate LD and associations between CRP genotypes and treatment response.
Main Results:
- No evidence of linkage disequilibrium (LD) was found between CRP and FCGR3A genes in either healthy donors or Crohn's disease patients.
- CRP polymorphisms did not significantly impact the decrease in CRP levels following infliximab treatment.
- No statistically significant differences in clinical or biological response rates were observed among different CRP genotypes.
Conclusions:
- CRP gene polymorphisms are not associated with infliximab treatment response in Crohn's disease.
- The findings exclude a role for CRP polymorphisms in predicting or influencing the efficacy of infliximab therapy in this patient cohort.
Related Concept Videos
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab (Humira),...
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel Disease...
01:25Inflammatory Bowel Disease III: Crohn's Disease
Crohn’s disease is a chronic, relapsing form of inflammatory bowel disease characterized by segmental, transmural inflammation that can affect any part of the gastrointestinal tract. Its pathogenesis arises from a combination of genetic susceptibility, environmental exposures, epithelial barrier dysfunction, and immune dysregulation. Together, these factors lead to an exaggerated immune response against components of the gut microbiome.Genetic and Environmental InfluencesMultiple genetic...
01:21Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2 (COX-2),...
01:29Inflammatory Bowel Disease IV: Pharmacological Management
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
01:30Inflammatory Bowel Disease II: Crohn's Disease
Introduction
Inflammatory bowel disease, commonly known as IBD, refers to a collection of disorders that lead to persistent inflammation of the gastrointestinal tract. The two types of IBD are ulcerative colitis, which impacts the colon, and Crohn's disease, which can involve any part of the gastrointestinal segment.
Crohn's disease
Crohn's disease is a chronic, systemic inflammatory bowel disease (IBD) that predominantly affects the gastrointestinal tract. It is marked by transmural...
Inflammatory bowel disease, commonly known as IBD, refers to a collection of disorders that lead to persistent inflammation of the gastrointestinal tract. The two types of IBD are ulcerative colitis, which impacts the colon, and Crohn's disease, which can involve any part of the gastrointestinal segment.
Crohn's disease
Crohn's disease is a chronic, systemic inflammatory bowel disease (IBD) that predominantly affects the gastrointestinal tract. It is marked by transmural...